Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 versus tiotropium crossover study in symptomatic COPD
2013-004223-37Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of indacaterol + glycopyrronium and tiotropium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: FEV1 1 hour post-inhalation after 4 weeks. Started Feb 2014; status: completed.
02
Drugs
indacaterol + glycopyrroniumtiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2013-004223-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004223-37.